Table 3. Fluorofenidone and losartan are without effects on diabetic pathogenesis of db/db mice.
| db/m | db/db | |||||||||
| 5 week | 8 week | 12 week | ||||||||
| Mock | FD | LOS | Mock | FD | LOS | Mock | FD | LOS | ||
| TG | 0.41±0.05 | 1.04±0.15* | 1.00±0.11* | 0.96±0.11* | 1.16±0.22* | 1.12±0.29* | 1.14±0.21* | 1.09±0.14* | 0.89±0.19* | 0.91±0.21* |
| TC | 2.04±0.21 | 3.08±0.62* | 3.06±0.13* | 3.03±0.48* | 3.19±0.10* | 3.02±0.16* | 3.03±0.39* | 3.20±0.59* | 3.05±0.30* | 3.12±0.37* |
| GLU | 9.51±0.72 | 41.11±3.61* | 41.17±2.78* | 37.86±6.22* | 44.84±3.45* | 41.76±5.08* | 42.81±3.89* | 42.73±3.51* | 41.19±9.90* | 38.50±7.54* |
| GSP | 4.96±0.21 | 6.47±0.21* | 6.34±0.19* | 5.42±0.27*†b | 6.44±0.62* | 6.17±0.89* | 6.49±0.56* a | 6.30±0.28* | 6.16±0.49* | 6.27±0.35* a |
| BW | 33.02±0.44 | 50.97±2.95* | 47.75±4.83* | 47.97±3.64* | 52.12±3.94* | 46.68±3.46* | 49.60±6.26* | 52.75±4.70* | 50.13±5.39* | 51.93±2.05* |
Six mice were used in each group.
TG: triglyceride (mmol/L); TC (mmol/L): cholesterol; GIU (mmol/L): blood glucose; GSP (mmol/L): glycated serum protein; BW (g): body weight; FD: Fluorofenidone; LOS: Losartan.
*p<0.05 vs. db/m mice; †p<0.05 vs. the respective mock groups; a p<0.05 vs. the 5-week group within the individual treatments; b p<0.05 in comparison between the respective FD and LOS treatments within the same intervention schedule.